Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD | Zendy

Robert Provenzano | Zendy; Anatole Besarab | Zendy; Chao Sun | Zendy; Susan A. Diamond | Zendy; John H. Durham | Zendy; José L. Cangiano | Zendy; Joseph R. Aiello | Zendy; James E. Novak | Zendy; Tyson Lee | Zendy; Robert Leong | Zendy; Brian K. Roberts | Zendy; Khalil G. Saikali | Zendy; Stefan Hemmerich | Zendy; Lynda A. Szczech | Zendy; Kin-Hung P. Yu | Zendy; Thomas B. Neff | Zendy

Open Access

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Author(s) -

Robert Provenzano,

Anatole Besarab,

Chao Sun,

Susan A. Diamond,

John H. Durham,

José L. Cangiano,

Joseph R. Aiello,

James E. Novak,

Tyson Lee,

Robert Leong,

Brian K. Roberts,

Khalil G. Saikali,

Stefan Hemmerich,

Lynda A. Szczech,

Kin-Hung P. Yu,

Thomas B. Neff

Publication year - 2016

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.06890615

Subject(s) - medicine , hemoglobin , anemia , gastroenterology , adverse effect , clinical endpoint , surgery , endocrinology , randomized controlled trial

Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research